Isotopia and CPDC ships first doses of Lu-177

By staff writers

June 9, 2022 -- Isotopia Molecular Imaging and the Center for Probe Development and Commercialization (CPDC) said the first doses of no-carrier-added (n.c.a.) lutetium-177 (Lu-177) have been shipped to clients in North America.

No-carrier-added Lu-177 is a commonly used radiometal for targeted radiation therapy, and its popularity has been growing. Therefore, there is a need for a constant supply of Lu-177.

The milestone achieved by Isotopia and CPDC means that a new production site in North America has been added, strengthening the n.c.a. Lu-177 supply chain, according to the companies.

"We have successfully achieved a stable and reliable n.c.a. Lu-177 supply in North America," said CPDC Chief Executive Officer Dr. Bruno Paquin, in a news release.

Isotopia inked a deal to supply CPDC with Lu-177 last year.

Copyright © 2022

To read this and get access to all of the exclusive content on create a free account or sign-in now.

Member Sign In:
MemberID or Email Address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking